ASA “Extremely Troubled” About Removal of Sodium Thiopental From Market

The American Society of Anesthesiologists says it is “extremely troubled” to learn that the anesthetic sodium thiopental, or Pentothal, has been removed from the U.S. market after its sole manufacturer ceased production of the drug, according to an ASA release.

Advertisement

According to the ASA, sodium thiopental is an “important and medically necessary anesthetic agent that has been used for years to induce anesthesia in patients undergoing surgical procedures.” While the drug’s use has dropped in recent years with the introduction of propofol and other medications, sodium thiopental is still extremely valuable, especially in cases involving geriatric, neurologic, cardiovascular and obstetric patients.

Read the ASA release on sodium thiopental.

Read more on anesthesia:

ASA Clarifies Medically-Induced Coma Versus Sedation

Facility Use of Blood Glucose Monitors Leads to Treatment Errors, Anesthesiologist Warns

Study: Improved Ultrasound Imaging of Injected Anesthetics on the Horizon

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Unlocking Structural Heart Capacity: How Leading Programs Use EMR and Data to Improve Patient Flow and Throughput

Wednesday, August 19
11:00 AM - 12:00 PM CDT

Presenters: Katie Kennedy, MSN, APRN, NP-C, Community Heart and VascularMisty Theriot, BSN, RN, CPHQ, FACC, Lake Charles Memorial Health SystemKatie Worthington, DNP, RN, Atlantic Health SystemTaryn Shipley, MBA, CSSBB, Lean HealthTech

Advertisement

Next Up in Anesthesia

Advertisement

Comments are closed.